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Background: We investigated the eﬃcacy and safety of strict voltage-based substrate
mapping and radiofrequency catheter ablation (SV-substrate-map ablation) in patients with
electrical storm.
Methods and Results: SV-substrate-map ablation was performed in 15 patients suﬀering
from multiple appropriate shocks (6:0 3:8/day) from implantable cardioverter deﬁbrillators
(ICDs). Strict voltage criteria were deﬁned as: non-arrhythmogenic areas, >0:6mV; low
voltage areas, >0:1 to 0:6mV; and scar, 0:1mV. Using an electroanatomic mapping
system, catheter ablation was performed at every possible arrhythmogenic region inside the
low voltage areas. Further, we presented a review of the literature and investigated the
published data on substrate-mapping guided ablation for electrical storm. After repeat
endocardial ablation procedures in 4 patients and an epicardial approach in one, the targeted
ventricular tachycardias (VTs) were successfully ablated, and the electrical storms were
completely controlled in all. During a mean follow-up period of 801 409 days, only one VT
followed by an appropriate ICD shock was observed. No potential complications occurred
during the procedure or follow-up. Our results were comparable or better than that of previous
substrate-mapping guided ablation studies.
Conclusion: SV-substrate-mapping ablation may be eﬀective and safe for resolving serious
clinical situations and prolonging the longevity of ICD devices in patients with electrical
storms.
(J Arrhythmia 2009; 25: 193–202)
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Introduction
Although implantable cardioverter deﬁbrillators
(ICDs) have become the main therapeutic tool for
patients with life-threatening ventricular arrhyth-
mias,1–3) patients with an ICD often require con-
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comitant therapy with antiarrhythmic agents to
decrease the frequency of deﬁbrillator therapies.4)
Despite concomitant antiarrhythmic therapy, some
patients still have frequent episodes of ventricular
tachycardia (VT), resulting in numerous shocks or
antitachycardia pacing therapies. In such a setting,
radiofrequency (RF) catheter ablation may be eﬀec-
tive for preventing frequent ICD deliveries of
electrical storms as well as for curing VTs.5–12)
Recent advances in the electroanatomic mapping
system (CARTO, Biosense Webster, Diamond Bar,
California, USA) has enabled us to create substrate
maps of the cardiac chambers, to precisely identify
margins of scar, return precisely to areas of interest,
visualize lines being created, and perform ablation
during sinus rhythm in unstable patients with
VT.5–11) Substrate-guided catheter ablation has be-
come a useful alternative to more conventional
ablation methods.5–11) However, its safety and
success rate is not suﬃciently high.5–11)
Recently, RF ablation targeting the low-voltage
areas detected by strict voltage criteria guided
ablation (SV-substrate-map-ablation) has emerged
as an eﬃcient and eﬀective treatment for curing
post-infarct VT.13) However, it is unclear whether or
not SV-substrate-map ablation is similarly eﬀective
and safe in VT patients with non-ischemic heart
disease or whether this method is also eﬃcient and
eﬀective for preventing frequent ICD shocks. To
clarify this, we continued the VT ablation by using
our original method.
The purpose of this study was to address the points
identiﬁed above. In this article, a search of the
medical literature on substrate-mapping guided
ablation for electrical storms was also conducted,
and the eﬃcacy and safety of the SV-substrate-
mapping guided ablation were compared with those
of the conventional substrate-guided ablation method
in patients with an electrical storm.
Methods
Study Population
From November 2004 to February 2008, 15
consecutive patients (13 men and 2 women; mean
age, 64 9 years) that underwent SV-substrate-
mapping guided ablation for electrical storms were
included after a detailed review of the clinical
records of 167 patients who received transvenous
ICDs for malignant ventricular arrhythmias. The
mean left ventricular ejection fraction (LVEF) was
35 15% (range, 15 to 58). Eight patients (53%)
had a previous myocardial infarction, 5 (33%)
idiopathic dilated cardiomyopathy, 1 (7%) cardiac
sarcoidosis, and the remaining patient (7%) valvular
heart disease (Tables 1 and 2). There was no evidence
of ischemia, cardiac failure, drug intoxication, or an
electrolyte imbalance.
All patients had a history of frequent and recurrent
episodes of VT attacks (6:0 3:8/day; range, 3 to
15/day) (Table 2) and were in a state of electrical
storm at the time of the ablation procedure, which
was deﬁned as three or more episodes of VT during a
24 hour period that resulted in a proper ICD shock.
In all patients, the clinical VT was documented by a
12-lead ECG at least once; 11 patients (73%) had
only one clinical VT, 3 (20%) had 2 VTs, and the
remaining 1 (7%) had 3 VTs (Table 1). All patients
had been treated with antiarrhythmic drugs for
ventricular arrhythmias (Table 1): Fourteen patients
(93%) received a -blocker, 12 (80%) amiodarone,
and 2 (13%) sotalol. The cardiac function was
evaluated by echocardiography before and after the
ablation procedure.
ICD systems
All patients received a transvenous lead system
via the subclavian vein and a pulse generator in
the left pectoral region (n ¼ 12, Medtronic Inc.,
Minneapolis, MN, USA; n ¼ 3, St. Jude Medical
Inc., Sunnyvale, CA, USA). A dual chamber trans-
venous ICD system was used in all patients.
Endocardial Mapping and Ablation
After informed written consent was obtained,
electrophysiological testing and catheter ablation
were performed based on our recently reported
strategy.13) Three quadripolar electrical catheters
were introduced percutaneously via the femoral vein
and positioned under ﬂuoroscopic guidance in the
high right atrium, His-bundle region, and RV apex.
After the catheters were positioned in the heart,
5,000U of heparin were administered intravenously.
The activated clotting time was kept at 250–300 sec
during the procedure. A 7 Fr Navistar catheter
(Biosense Webstar) with a 4-mm distal tip electrode
and 2-mm ring electrodes with 1-mm interelectrode
spacing was used. The bipolar signals were ﬁltered
between 30 to 400Hz and displayed at a sweep
speed of 100mm/s on the CARTO system. The ﬁll
threshold was set at 10mm. The peak-to-peak signal
amplitude of the bipolar electrogram was measured
automatically and conﬁrmed manually. We deﬁned a
non-arrhythmogenic area as that having an ampli-
tude of >0:6mV, low-voltage area as that of >0:1 to
0:6mV, and scar area as that of 0:1mV without
capture by local bipolar stimulation at the maximum
output (10V and 2-ms pulse width) (Table 3 and
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Figure 1).13) All patients underwent SV-substrate-
mapping during sinus rhythm with a CARTO system
(Biosense Webstar).
During sinus rhythm, a substrate map was care-
fully created for identifying all, even tiny, low-
voltage areas. Arrhythmogenic regions could be
considered to be located between scar-scar, scar-
tricuspid/mitral annulus, and/or scar-non-arrhyth-
mogenic areas.13) An arrhythmogenic region of the
clinical VT was deﬁned as excellent pace map sites
with various stimulus-QRS intervals. If we found a
site where the paced QRS morphology was similar to
the clinical VT morphology, detailed pace mapping
around the site was undertaken to detect as much of
the entire arrhythmogenic region as possible. To
abolish not only the arrhythmogenic region of the
clinical VT detected by pace mapping, but also all
possible arrhythmogenic regions within the low
voltage areas, a linear ablation design was created
according to the following 3 guiding principles:13)
Table 1 Patient characteristics and all ventricular tachycardias.
LVEF No. of Antiarrhythmic
Clinical VT Inducible VT (Non-clinical)
No Age Gender Etiology (%) mapping drugs Morphology CL Morphology CLpoints
1 76 M MI (ant) 40 327 Amio RBRA 370 RBRA 450
2 57 M DCM 25 266 Amio + -blocker QSLA, QSLA, RBLA 600, 390, 300
3 50 F Sarcoidosis 51 362 Amio + -blocker RBRA 580 LBRA 600
4 57 M DCM 58 337 -blocker RBLA 290
5 45 M MI (ant) 53 281 Amio + -blocker RBLA 430
6 67 M DCM 18 322 Amio + -blocker RBRA 950
7 65 M MI (ant) 30 313 Amio + -blocker RBLA 550
8 66 M MI (inf) 15 366 Sotalol + -blocker RBLA 590 RBLA 300
9 57 M MI (inf) 38 421 Amio + -blocker RBLA 300 LBLA 280
10 71 M DCM 18 272 Amio + -blocker LBRA, LBLA 350, 280
11 69 M MI (ant) 17 85 Amio + -blocker LBLA, RBLA 300, 260
12 71 M DCM 29 175 Amio + -blocker LBNA 400
13 65 M MI (ant) 29 332 Sotalol + -blocker RBLA 400 RBRA, LBLA, 330
14 73 F VHD 55 172 Amio + -blocker RBLA 400 QSLA, RBLA 330, 330
15 74 M MI (ant) 43 177 Amio + -blocker RBNA, RBNA 550, 300 LBLA 300
Mean 64 M-13 35 281 430 358
SD 9 F-2 15 95 167 103
The values are the mean SD.
Amio: amiodarone, CL: cycle length, DCM: dilated cardiomyopathy, F: female, LA: left axis, LB: left bundle, LVEF: left ventricular
ejection fraction, M: male, MI: myocardial infarction, NA: normal axis, No.: number, NW: north west axis, QS: concordant QS pattern,
RA: right axis, RB: right bundle, VHD: valvular heart disease, VT: ventricular tachycardia
Table 2 Baseline characteristics of the 160 patients who underwent substrate-mapping guided ablation for
frequent ICD shocks.
No. of Age, LVEF, Use of class III No. of ICD shocks
Authors Patients years Etiology % AADs, % before ablation
Pre Post
Sra J et al.5Þ 19 70 7 Ischemic 27 8 100% 47% 4-62/3 months
Soejima K et al.6Þ 40 67 11 Ischemic 29 10 53% 63% 11.9  11.1/2 months
Soejima K et al.7Þ 20 54 14 Non-ischemic 30 11 68% 43% 2-100/month
Schreieck J et al.8Þ 5 61 17 Ischemic 18 7 100% 80% 3-310/2 weeks
Volkmer M et al.9Þ 13 65 9 Ischemic 30 8 88% 52% 1-930/6 months
Carbucicchio C et al.10Þ 48 64 13 Both 36 11 99% 88% 14 8/day
Our cases 15 64 9 Both 35 15 93% 93% 6.0  3.8/days
Values are mean SD. Epicardial substrate-mapping was performed in several patients.
AAD: anti-arrhythmic drug, ICD: implantable cardioverter deﬁbrillator, LVEF: left ventricular ejection fraction,
No.: number
Arimoto T Catheter ablation for electrical storm
195
(1) lesions must cross through the low-voltage area
at sites where an excellent pace map is obtained, (2)
lesions must extend between scar and scar within the
low-voltage area, and (3) lesions must extend from
the scar to the non-arrhythmogenic area (0.6mV). If
we could not suﬃciently identify the arrhythmogenic
region of the clinical VT by pace mapping, targeted
pathological myocardium was identiﬁed within the
low-voltage area by the observation of fragmented or
late potentials during sinus rhythm. In those cases,
linear RF energy applications were placed along the
abnormal potentials.
After the creation of the entire ventricular map,
programmed stimulation with up to 3 extrastimuli
was ﬁrst performed from the NaviStar catheter
located near the optimum mapping site, then at
the RV apex, and ﬁnally the RV outﬂow tract, if
necessary, to induce VT. If the induced VT was
tolerated hemodynamically, entrainment mapping
was performed. An electrically-induced VT was
considered the same as a clinical VT when its surface
QRS conﬁguration (QRS duration, frontal and
horizontal axes, and bundle branch block morphol-
ogy) was the same as the spontaneous VT and when
the diﬀerence in the VT cycle length between the
induced VT and clinical VT was <40ms.
As a rule, RF deliveries were not performed in
non-arrhythmogenic areas (>0:6mV). The RF en-
ergy was delivered via a 7 Fr 4-mm-tip NaviStar
catheter in temperature-controlled mode for 60–
90 sec at each ablation site at a maximal target
temperature of 55 C and maximum power of 50W.
The endpoint of the RF delivery was the loss of
bipolar pacing capture at a 5-V output and 2-ms
pulse width immediately after the RF energy
application and by the elimination or signiﬁcant
reduction in the fragmented or late potentials. After
the RF delivery at each site, if pacing could capture
the ablation site additional RF energy at the same
setting was reapplied to the same site for 30–60 sec.
If the 4-mm-tip NaviStar catheter could not deliver
>20W of power because of temperature limiting
eﬀects, a conventional 8-mm-tip ablation catheter
(Ablaze, Japan Lifeline, Tokyo, Japan) was used for
energy delivery. An 8-mm-tip catheter was also
adopted in patients undergoing a second endocardial
procedure. In such cases, because the open-irrigation
catheter was not available in Japan at that time, we
had to insert 2 catheters simultaneously into the
ventricle: the 4-mm-tip NaviStar catheter, which was
used only for mapping, and the 8-mm-tip conven-
tional catheter which was inserted from the con-
tralateral femoral vessel and used only for ablation.
We positioned both catheters at the same site under
guidance with ﬂuoroscopy and the local potentials,
and delivered the RF applications with the 8-mm-tip
catheter at the target site navigated with the 4-mm-
tip NaviStar catheter. The endpoint of the procedure
was the non-inducibility of any clinical VT by
programmed stimulation with up to 3 extrastimuli.
Epicardial Mapping and Ablation
Epicardial mapping was performed in case 2 using
a percutaneous transcardial approach as reported
previously.7,14) Brieﬂy, the epicardial ablation uti-
lized a subxiphoid approach with an epidural needle
using a 10ml syringe with contrast media, the needle
was advanced toward the left scapula guided by
ﬂuoroscopy. When the pericardial space was thought
to be reached, a small bolus of 1ml of contrast
agent was injected. A 7 Fr sheath used for standard
ablation was advanced over the guidewire which was
introduced into the pericardial space. A 4-mm-tip
NaviStar catheter was introduced through the sheath
Table 3 Electrophysiological data and the results and long-term outcome of substrate-mapping guided ablation in 160 patients
with frequent ICD shocks.
No. of VT-CL, Criteria No. of RF Procedure Long-term
Complication
Follow-up
Authors target ms of LVAs applications time, min success Death Others duration (days)VTs rate
Sra J et al.5Þ 2.0  0.7 250–440 <1.0 mV 9 4 lesions NA 66% 0 1 182 56
Soejima K et al.6Þ 3.6  2.1 263–690 <1.5 mV 18.1  11.2 425 222 47% 0 4 349 286
Soejima K et al.7Þ 2.9  1.7 215–520 <1.5 mV 17.7  9.4 NA 54% 0 1 334 280
Schreieck J et al.8Þ 5.0  1.9 240–550 <1.5 mV 75 48 340 79 60% 0 0 570 240
Volkmer M et al.9Þ 3.0  2.0 429 82 <1.5 mV 14  6 474 124 54%! 71%# 1 0 750 390
Carbucicchio C et al.10Þ 1–5 381 62 <1.5 mV NA 260 70 66% 0 8 660 390
Our cases 2.0  0.8 430 167 <0.6 mV 19 13 252 74 67%! 93%# 0 0 801 409
Values are mean SD. Success was deﬁned as freedom from any episodes of ventricular tachycardia. #The success rate
improved after the 2nd procedure.
CL: cycle length, LVA: low voltage area, NA: not available, No.: number, RF: radiofrequency, VT: ventricular tachycardia
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into the pericardial sac. The exposed epicardial
surface was mapped during sinus rhythm using
ﬂuoroscopy and an electroanatomic mapping system
with our original elaborate voltage criteria. The RF
deliveries were similarly performed from the endo-
cardial approach, as mentioned previously.
Follow-up
The patients remained hospitalized under contin-
uous rhythm monitoring for 1–2 weeks after the
ablation procedure. After leaving the hospital, the
patients underwent follow-up at 2 weeks post-
procedure, and then every 1 to 2 months thereafter
at our cardiology clinic. Any delivered ICD therapies
were noted. When interrogation of the ICD allowed
determination of the treated VT cycle length, the
treated VT was considered consistent with the
ablated VT if the cycle length of the treated VT
was within 20ms of the ablated VT cycle length.
Literature search and data collection
Using the PubMed database (MEDLINE, National
Library of Medicine), we conducted a comprehen-
sive search of the literature encompassing the period
from 1998 to 2008. We searched for the key words
‘‘ventricular tachycardia,’’ ‘‘substrate,’’ ‘‘mapping,’’
‘‘ICD’’, ‘‘electrical storm’’ and/or ‘‘catheter abla-
tion’’. We then reviewed the articles identiﬁed by our
search using prospectively deﬁned inclusion criteria.
The articles were considered for inclusion if they
were published in the English language and describ-
ed at least ﬁve cases of substrate-mapping guided
ablation for an electrical storm. From the obtained
data, we examined the clinical, ECG, and electro-
physiological characteristics of the electrical storm,
and compared our results of SV-substrate-mapping
guided ablation with those of previous studies
(Tables 2 and 3).
Statistical analysis
The continuous variables are expressed as the
mean SD, and were compared using the Student’s
t test. A p value of <0:05 was considered signiﬁ-
cant.
b: -28 c: -60 d: -74a: -24Clinical VT
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Figure 1 Representative case of strict voltage-based substrate-mapping in a patient with an inferior infarction (case 9).
Elaborate original voltage criteria were used to deﬁne the non-arrhythmogenic area as >0:6mV (purple); low-voltage area as >0:1 to
0:6mV (blue to red); and scar as 0:1mV (gray). The brown and blue tags represent the ablation site and optimum pace map sites,
respectively (a-d). The 12-lead electrogram exhibits the clinical ventricular tachycardia (VT) and pace maps at sites a-d. The number
following each letter indicates the stimulus-QRS intervals; the QRS morphology at all sites is identical to the clinical VT morphology. The
‘‘a’’ site is considered to be the exit of the VT reentrant circuit.
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Results
Electrophysiological study, VT characteristics
and results of the RFCA
The VT originated from the LV in 13 patients
(87%), and the RV in the remaining 2 (13%). With
programmed ventricular stimulation, the mean
number of induced monomorphic VTs was 2:0
0:8 (range, 1 to 3), and mean cycle length of the
clinical VTs 430 167ms (Tables 1 and 3). Clinical
VTs were inducible in 13 patients (87%) during the
ablation procedure. Entrainment mapping during the
VT could be obtained only in 5 patients (33%)
because of hemodynamic instability. The number
of optimal pace map points was 4:9 2:0 points/
patient (range 3–8). The number of mapping sites
was 281 95 points/patient (range 85–421)
(Table 1).
In the ﬁrst ablation procedure with the endocardial
approach, the clinical VTs were successfully elim-
inated in 10 patients (67%) (Table 3, Figures 2A and
2B). In the remaining 5 patients (33%) who suﬀered
a recurrence of VT within a week after the ﬁrst
procedure, a second ablation session was performed
within a week from the ﬁrst procedure. In 4 patients
(27%) with recurrent VT, the targeted VTs were
controlled with a second endocardial procedure.
However, no targeted areas were found during
mapping from the endocardial sites of both ventri-
cles in the remaining patient. Therefore, an epicar-
dial approach was performed, and the clinical VTs
were successfully ablated in the second procedure
(Figure 2A). Finally, in all patients, the frequent ICD
deliveries were completely controlled after the
second procedure (Figure 2B).
During the electrophysiological testing, 9 non-
clinical VTs that had a diﬀerent QRS morphol-
ogy than the clinical VTs were also induced in 7
patients (47%) (Table 1). In 4 patients (27%), no
types of VT were ever induced during or after the
procedure (Figure 2A). The total duration of the
ablation procedures was 252 74min. The total
number and duration of the RF energy applica-
tions were 19 13 and 23 17min, respectively
(Table 3).
Follow-up
The LVEF and left ventricular end-diastolic
dimension (LVEDD) measured by echocardiography
1 week after the ablation procedure were 36 14%
and 61 12mm, respectively, both of which were
not signiﬁcantly diﬀerent from those measured
before the procedure (LVEF, 35 15%; LVEDD,
61 12mm).
During a mean follow-up period of 801 409
days (median 677 days; range, 397–1583), VT and
appropriate ICD shocks were observed in only 1
patient (7%) (Figure 3). No complications were
observed during or after the RFCA procedure and
no inappropriate ICD shocks occurred during the
follow-up period. No patients died during the follow-
up period (Table 3).
Literature review
The selected features from 145 cases of substrate-
mapping guided ablation for frequent ICD shocks
and from the present 15 cases are summarized in
Tables 2 and 3.5–10) Although all previous reports and
our present study performed substrate mapping with
the CARTO system, the detailed mapping strategy,
settings of the RF delivery, and ablation catheters
diﬀered with each article.5–10) There were substan-
tially more males (89%) than females (11%). A
majority (78%) of patients had a previous myocar-
dial infarction, and the mean LVEF was 30 6%.
All had been given ICDs for ventricular arrhythmias
and suﬀered from frequent appropriate ICD shocks.
The baseline characteristics, including the preva-
lence of the use of antiarrhythmic drugs and
frequency of appropriate ICD shocks in our cases
were compatible with those in the previous studies
(Table 2).
The electrophysiological data, results and long-
term outcomes of substrate-mapping guided ablation
are shown in Table 3. In all studies except for our
study, the low-voltage area was deﬁned during sinus
rhythm by electrograms with an amplitude of<1:0 or
1.5mV; dense scar was deﬁned by electrograms with
an amplitude of <0:5mV. SV-substrate-mapping
was only adopted in our study. The overall success
rates after conventional substrate-mapping guided
ablation was 47% to 67% after the ﬁrst procedure,
and potential complications occurred in some pa-
tients: 1 patient (0.6%) died in the hospital after the
procedure,9) and other procedure-related complica-
tions were reported in 14 cases (8.8%).5–7,10) Com-
pared with the results of the conventional substrate-
mapping guided ablation, the total procedure dura-
tion was shorter in our results of SV-substrate-
mapping guided ablation. The long-term success rate
of our study increased up to 93% after a repeat
ablation procedure in 5 patients, which was higher
than that of the previous studies.
Discussion
Main ﬁndings
The results of the present study demonstrated the
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following ﬁndings: 1) In both the ischemic and non-
ischemic patients the SV-substrate-mapping guided
ablation abolished the clinical VT, then resolved the
electrical storm completely with no potential com-
plications; however, ﬁve of them required a second
ablation session; 2) During a moderate follow-up
period of >2 years, only one VT followed by an
appropriate ICD shock was observed; 3) Our results
and data of the ablation procedure and follow-up,
including the procedure and RF energy application
times, were comparable to or better than those of the
previous studies of substrate-mapping guided abla-
tion.
These ﬁndings indicate that the SV-substrate-
mapping guided ablation may be eﬀective and safe
for resolving serious patient situations and to prolong
the longevity of the ICD device in patients with
electrical storms, irrespective of the underlying heart
disease.
Clinical importance of reducing ICD therapies
A signiﬁcant decrease in ICD therapy deliveries
may be clinically important, not only for quality-of-
life, but also the reduction in subsequent adverse
cardiovascular events. Previous trials found an
increase in congestive heart failure and mortality in
patients receiving ICD shocks.1,2) Furthermore, both
appropriate and inappropriate ICD shocks are asso-
ciated with a marked increase in the subsequent risk
of cardiac death in patients with heart failure.15) The
negative inotropic consequences of multiple shocks
themselves could increase the risk of death.16,17)
These results imply the need for a more aggressive
application of catheter ablation for patients suﬀering
from frequent shock deliveries.
In the present study, we could suppress the
electrical storms completely with catheter ablation
in all patients. During the long-term follow-up
period after the ablation, only one appropriate ICD
shock and no inappropriate ICD shocks were
observed. Furthermore, no patients died during the
follow-up period. Therefore, in our study, there was
a high possibility that the signiﬁcant reduction or
abolishment of the VT attacks and the resulting
deﬁbrillator shocks by catheter ablation therapy
might improve the subsequent prognosis.
Case
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6
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9
10
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13
14
15
Clinical VT not inducible
No VT of any type inducible
Recurrence within a week
Endocardial
approach
Epicardial
approach
2nd procedure
Pre Post
1W
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1M
0
10
5
15
VT episodes / day
1st procedure
BA
Figure 2
A. Immediate ablation results.
Electrical storms in 10 patients (67%) were successfully controlled in the ﬁrst procedure. Four patients (27%)
underwent a second endocardial catheter ablation. An epicardial procedure was performed in 1 patient.
B. Acute ablation results.
The frequency of the VT episodes is shown for the period before (pre) and the following intervals: one week after the
ablation and from one week to one month after the ablation. M: month, VT: ventricular tachycardia, W: week
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Efﬁcacy and safety of strict voltage-based sub-
strate-mapping from an endocardial approach
The usefulness of ablating drug-refractory VT was
clearly demonstrated previously; however, the long-
term success rates did not reach suﬃciently accept-
able results.5–10) In the present study, the SV-
substrate-mapping guided ablation procedure had a
suﬃciently high acute success rate and better long-
term outcome compared to that of substrate-mapping
guided ablation with conventional voltage criteria.
The total procedure time in this study was similar to
previous catheter procedures, most of which was
spent on SV-substrate-mapping in this study. A
recent study showed that, using the SV-substrate-
mapping, the targeted arrhythmogenic area (0:6
mV) for the RF energy delivery was restricted
approximately to half the size compared to that of
the conventional targeted area with an amplitude of
1:5mV.13) Therefore, in SV-substrate-mapping, the
abnormal regions could be identiﬁed simply and
clearly during the procedure by restricting the target
regions within smaller arrhythmogenic areas, which
may result in a shorter procedure time compared to
the previous results.
Several ablation-related complications, including
anticipated complete atrioventricular block, transient
ischemic attacks, and pericardial eﬀusions, have been
reported in 14 patients (8.8%) who underwent
substrate-mapping guided ablation.5–7,10) Unfortu-
nately, 1 patient (0.6%) died in the hospital the night
after the procedure from electromechanical dissoci-
ation after cardiac tamponade (Table 3).9) On the
other hand, neither procedure-related deaths nor
cardiac complications were observed in the recent
studies of SV-substrate-mapping guided ablation,
including this study.13) In this study, SV-substrate-
mapping was also useful for determining the optimal
ablation sites in the patients with nonischemic heart
disease as well as those with ischemic heart disease.
Because the target sites of the RF energy applications
determined by SV-substrate-mapping were always
smaller than those determined by the conventional
voltage criteria, we think that the futile applications
of RF energy at the myocardium within or near the
low-voltage areas, which were not related to the VT,
could be avoided. Fewer applications of RF energy
might result in less injury to the myocardium and
avoidance of deterioration of LV function after the
ablation procedure. Further, fewer applications of RF
energy and a shorter procedure duration may also
contribute to a reduction in the complications, such as
heart failure or thromboembolic events, and result in
a favorable long-term outcome.
Strict voltage based substrate-mapping from an
epicardial approach
Recent studies demonstrated that the patients with
nonischemic cardiomyopathy sometimes had no scar
tissue in the LV endocardium, but exhibited a
profoundly large low-amplitude region in the LV
epicardium,18) and that reentrant VT associated with
nonischemic cardiomyopathy was successfully elim-
inated in only 54% of patients from the endocardial
approach.7) Therefore, epicardial mapping should
be considered when no suitable ablation sites exist
within the LV endocardium in patients with non-
ischemic heart disease. Indeed, in our case with
idiopathic dilated cardiomyopathy (case 2), no ap-
preciable low-voltage areas were visualized in the
LV endocardium and therefore no ablation lesions
were placed in the ﬁrst procedure. The clinical VTs
were eliminated and the electrical storm was
completely suppressed only by a catheter ablation
from an epicardial approach. Low-amplitude regions
were found from the LV anterior wall to the apex.
The targeted arrhythmogenic area (0:6mV) for
the RF energy deliveries was restricted approxi-
mately to half the size of the generally targeted area
with an amplitude of 1:5mV in this case. The
abnormal regions were easily delineated and made
lucid during the procedure only because SV-sub-
strate-mapping was employed. Therefore, we think
that SV-substrate-mapping may also be useful for
curing VT and avoiding complications compared to
the risks inherent with the futile and numerous
applications of RF energy with the epicardial
approach.14)
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Figure 3 Long-term ablation results.
Kaplan-Meier curve demonstrating an event-free rate of 93%
during the follow up period. Only one sustained ventricular
arrhythmia followed by appropriate shock was observed in case 13.
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Study limitations
First, the patients were systematically maintained
on the same oral antiarrhythmic regimen as before
the ablation. In particular, a majority of patients were
treated with oral amiodarone after the procedure.
These drugs probably contributed to the slowing
of the VT and may have rendered the VT more
amenable to mapping and ablation. Without the
concomitant use of antiarrhythmic drugs, our imme-
diate success rate and long-term outcome may have
been lower. Actually, in case 13, drug-induced
bradycardia later developed, so sotalol and the -
blockers were discontinued. Unfortunately VT and
appropriate ICD shocks were observed two weeks
after the reduction of those drugs. Hence, we can
assume that ablation and drug therapy will remain
important components in managing patients with
frequent ICD therapies.
Second, the previous studies reported that the VT
isthmus resided not only in dense scar (<0:5mV),
but also in the border zone (>0:5 to <1:5mV).19,20)
On the other hand, Hsia et al. demonstrated that
47/56 (84%) of VT entrance or isthmus sites were
located in <0:5mV regions.21) In agreement with the
previous results,13,21) we reached a suﬃciently high
success rate without any RF energy applications to
preserved voltage areas (>0:6mV). However, the
reason for the diﬀerence between the previous
results5–10,19,20) and SV-substrate-mapping guided
procedure is still unclear.
Third, we created a linear ablation lesion to
abolish not only the arrhythmogenic region of the
clinical VT detected by pace mapping but also all
possible arrhythmogenic regions. Moreover, if we
could not completely identify the arrhythmogenic
region of the clinical VT by pace mapping, RF
energy was delivered to putative pathological re-
gions with fragmented or late potentials. One of
the endpoints of the RF deliveries was the elimi-
nation or signiﬁcant reduction in abnormal poten-
tials. Additional RF deliveries at those sites may
have improved the clinical outcome in the present
study.
Finally, the number of patients was not large
enough, so a large-scale completely prospective
study may be needed to further assess the prognostic
value of SV-substrate-mapping guided ablation
compared to conventional substrate-mapping guided
ablation.
Conclusions
Electrical storms were completely suppressed in
all non-ischemic patients as well as ischemic patients
by SV-substrate-mapping guided catheter ablation.
The clinical VTs were successfully eliminated and
the clinical outcome was also suﬃciently good.
Additionally, no procedure-related deaths or any
complications were observed during the long-term
follow-up period. Our elaborate voltage criteria
guided catheter ablation may be one of the ideal
strategies for patients with frequent ICD shocks.
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